Strategic Spinoffs and Bold Overhauls Across 10 Under-the-Radar Stocks

While the broader market remains fixated on mega-cap narratives, I'm told that a quieter but equally significant overhaul is happening across diverse industry pockets. From utility infrastructure to healthcare and spirits, executives are increasingly prioritizing operational focus over sprawling portfolios. According to people familiar with the matter, this internal drive for leaner structures is setting the stage for the most significant restructuring wave we’ve seen in these niche sectors later this year.

American Water Works (AWK.US)

The largest publicly traded U.S. water utility is steadily securing the capital needed for its massive USD 48B, decade-long infrastructure overhaul. I'm told its Pennsylvania subsidiary scored a crucial win in July 2026, gaining PUC approval for an estimated USD 74.9M annual revenue increase. Buoyed by Q4 2025 revenues of USD 1.3B (up 5.8% year-over-year), the company also saw UBS bump its price target to USD 150 recently, maintaining a buy rating.

Harmonic (HLIT.US)

This is arguably the most significant overhaul in Harmonic’s recent history. The company officially completed the spin-off of its video business to MediaKind in June 2026, effectively transforming into a pure-play broadband company. I’m told this streamlined focus is already paying dividends globally, with telecom operators like Finland's DNA and Venezuela's Inter tapping Harmonic's technology to bolster their 5G and fiber networks.

Solventum (SOLV.US)

The medical device maker is moving aggressively in the advanced wound care space. Having completed a USD 725M upfront acquisition of Acera Surgical, the company is aiming to solidify its portfolio. While Q4 2025 net sales dipped slightly to USD 1.998B, organic growth actually rose 3.5%. According to internal projections, management expects 2026 organic sales growth to land between 2.0% and 3.0%, setting a stable baseline before their next earnings report.

Tencent (TCTZF.US)

Tencent's cross-border ambitions are accelerating. Beyond testing the TenPayGo app for foreign tourists, the Chinese tech conglomerate is targeting a massive USD 4.66B raise via dollar- and yuan-denominated notes. I'm told this war chest could be deployed for further international expansion. Following an earnings beat with an EPS of USD 0.363, the upcoming August 2026 report will be closely watched for more strategic breadcrumbs.

Cardinal Health (CAH.US)

Cardinal Health is flexing its pricing and volume leverage. The healthcare distributor posted a massive 19% revenue surge in its fiscal Q3 2026, hitting USD 65.6B. According to people familiar with their supply chain operations, the April expansion of their Actinium-225 manufacturing capabilities is perfectly timed to meet surging demand for novel cancer therapies. Management was confident enough to raise their fiscal 2026 non-GAAP diluted EPS guidance to at least USD 10.00.

TAL Education (TAL.US)

The pivot to smart learning solutions continues to pay off for TAL. Fiscal 2026 revenue jumped 34% year-over-year to USD 3.01B, paired with a solid net income of USD 530.8M. However, I'm told the company is simultaneously navigating internal executive shuffles—such as former CTO Mi Tian moving to a Senior VP role in April 2026—and ongoing securities class action litigation.

Cohu (COHU.US)

Semiconductor test equipment supplier Cohu is quietly capitalizing on the AI infrastructure build-out. Despite Q1 2026 net sales coming in at USD 125.1M, the company snagged roughly USD 5M in fresh orders for next-gen AI data center GaN power device testing in May. I'm told this momentum prompted them to revise their fiscal 2026 high-performance computing revenue forecast upward to the USD 80M to USD 100M range.

Also

• Gelteq (GELS.US): Despite posting an interim loss of AUD 0.36 per share in H1 2026, the edible gel maker established a Center of Excellence in China this June, which I'm told is critical for accelerating its global commercial footprint.
• Apollomics (APLM.US): The clinical-stage biopharma company narrowly avoided a delisting scenario. After receiving a USD 2M convertible note financing directly from its CEO, Apollomics officially regained Nasdaq compliance in July 2026.
• Diageo (DEO.US): The spirits giant is bracing for impact. With flagship brands suffering prolonged volume declines in the U.S. market, the new CEO has ordered a comprehensive restructuring to slash costs before the next earnings call.

This article does not constitute investment advice.